Caribou Biosciences (CRBU)

• Market cap: $199M
• 1 day: -2.28%
• 5 days: -7.36%
• 1 month: -8.55%
• 3 months: 13.83%
• 6 months: 183.71%
• Year to date: 27.38%
• 1 year: -22.18%
• 5 years: -86.89%
• 10 years: -86.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147